Introduction
Hervé and Lembit welcomed the group. Lembit updated members on the webinar that WG XI hosted recently subsequent to the publication of the report on “Patient involvement in the development, regulation and safe use of medicines”. He suggested the SCAR WG could hold a webinar as well to promote the report.

Key actions/decisions
- An updated draft will be circulated to the WG for comment. (Catherine)
- The WG should also review the table in Chapter 2 (section 2.5.2).
- The EC is tasked with reviewing comments and resolving any open questions.
- Endnotes should be included at the end of each chapter, not the end of the report (Catherine)
- Chapter leads should determine if they wish to include chapter highlights and key messages at the beginning of each chapter (Chapter leads)
- Bibliographical references should be included as endnotes in the text (Re Chapters 4, 7, 8)
- A list should be provided of key terminology to be included in the Glossary (Chapter leads)
- Photos should be selected to be included as links in Clinical characteristics section for each SCAR (Chia-Yu)
- INN’s to be inserted as appropriate (Chapter 8)
- Review tables in Appendix A (see Drugs Y and Z). Determine if appropriate and if similar tables be inserted for Drugs X, A and B. (Chapter 8)

- Liaise with CIOMS Glossary WG re adding “Marketing Authorization” to CIOMS Glossary. (added 21 March)
- Deleted section 5.1.2 Causality- a diagnostic criterion for SCAR (added 21 March)

Timeline:
Mid-end April: 2nd Editorial Committee
Mid-May: new draft to be shared with WG
End May/early June 10th WG
First week of June: Final changes
June 15th: Report available for public consultation